Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 9/20 | 0.49 |
| ▸ | SCTR | P47872 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | TFPI | P10646 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168588 | 0.98 | APLNR (0.54) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10168792 | 0.94 | APLNR (0.54) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10168706 | 0.92 | APLNR (0.54) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10168576 | 0.92 | APLNR (0.55) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10168583 | 0.91 | APLNR (0.51) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10169091 | 0.91 | APLNR (0.48) | APLNRKISS1R | |
| SCHEMBL10168808 | 0.91 | APLNR (0.55) | APLNRC5AR1GLP1RSCTRGCGR | |
| SCHEMBL10169097 | 0.88 | APLNR (0.50) | APLNRC5AR1GLP1RSCTROPRL1 | |
| SCHEMBL10168616 | 0.88 | APLNR (0.49) | APLNRGLP1RSCTRGCGRIL23R | |
| SCHEMBL10168697 | 0.87 | APLNR (0.50) | APLNRC5AR1GLP1RSCTRGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | APLNR 1/4885C5AR1 1057/4885GLP1R 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.